Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Tandem Diabetes (TNDM) to $13 from $20 and keeps an Equal Weight rating on the shares. The firm notes the company delivered an in-line quarter and updated its FY25 guidance, including a $25M-$30M cut to FY25 U.S. sales. Management pointed to increased competitive headwinds and slower rep ramp. The firm sees less visibility into 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes downgraded to Neutral from Overweight at Piper Sandler
- Tandem Diabetes Care Reports Record Q2 2025 Sales
- Tandem Diabetes Care: Strong Revenue Performance and Promising Portfolio Justify Buy Rating Despite Challenges
- Closing Bell Movers: DoorDash jumps 8%, Airbnb slips 6% on earnings
- Tandem Diabetes reports Q2 EPS (78c), consensus (40c)